nVerses Capital’s Astria Therapeutics ATXS Stock Holding History

nVerses Capital’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-800	Closed	-$8.81K	–	84
2024 Q3	$8.81K	Buy	+800	New	+$8.89K	﹤0.01%	902

Other funds holding ATXS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

nVerses Capital's ATXS Position: Q4 2024 in Review

nVerses Capital sold out of Astria Therapeutics (ATXS) in Q4 2024, closing a stake of 800 shares — an estimated $8.81K sold.

nVerses Capital first reported a position in ATXS in Q3 2024 and held it in 1 quarter. The position peaked at $8.81K in Q3 2024. 110 funds tracked by Wall St. Rank hold ATXS as of Q4 2024.

nVerses Capital reported no remaining Astria Therapeutics position as of Q4 2024 after selling out during the quarter.
nVerses Capital sold 800 Astria Therapeutics shares in Q4 2024, an estimated $8.81K.
nVerses Capital first reported a position in Astria Therapeutics in Q3 2024 and held it in 1 quarter.
nVerses Capital's Astria Therapeutics position peaked at $8.81K in Q3 2024.
110 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.